Quality healthcare is a human right ICMR Registration
No : SHMTL MC-3912
TESTING LAB
GISPL.ML1
(820610)
Azadpur, New
Delhi
Patient ID: SH1534431 Sample ID: 0707700740541
Name: GAURABMV Sample Collected: 27/03/2021 (Pre-Collected Sample)
Address: KASHMERE GATE DELHI
Sample Received: 27/03/2021 17:05
PIN:,CENTRAL, Age: 25 YEARS, Gender:
Report Generated: 29/03/2021 18:43
MALE
Report Status: FINAL
Mobile Number: 7428803203
TEST REPORT
Test Method SARS CoV-2 Qualitative
RT PCR Specimen Type Nasopharyngeal
& Oropharyngeal
Gene 1: ORF1ab NA
Gene 2: N NA
Result Negative
INTERPRETATION
RESULT REMARKS
Positive RNA Specific To SARS-COV-2 Detected
Negative RNA Specific To SARS-COV-2 Not Detected
Inconclusive A Repeat Sample Is Suggested In Case Of Clinical Suspicion
Non Diagnostic Internal control not detected, samples need to be repeated
ABOUT SARS COV 2 LIMITATIONS
SARSCoV2, formerly known as 2019nCoV, is the causative agent of the 1. Negative results do not preclude COVID19 and should not be used as the
coronavirus disease 2019 (COVID19). Main symptoms of the disease sole basis for patient management decisions. Negative results must be
include fever, cough and shortness of breath. The virus is spread via combined with clinical observations, patient history, and epidemiological
persontoperson contact through respiratory droplets produced when a information.
person coughs or sneezes. The SARSCoV2 2. Positive results but do not rule out bacterial infection or coinfection
RNA is generally detectable in nasopharyngeal/oropharyngeal swabs with other viruses.
during the acute phase of infection. Positive results are indicative of 3. Optimum specimen types and timing for peak viral levels during
active infection. Real Time PCR assay targets specific genes and can be infections caused by 2019nCoV have not been determined. Collection of
used for diagnosis of SARSCoV2 virus infection which contributes to multiple specimens (types and time points) from the same patient may be
severe upper respiratory distress, complications necessary to detect the virus.
4. If the virus mutates in the rRTPCR target region, 2019nCoV may not be
detected or may be detected less predictably. Inhibitors or other types of
interference may produce a false negative result.
5. The performance of this test has not been established for monitoring
treatment of
2019nCoV infection.
Dr Neha Kaushal Dr. Ruchika Manchanda
Consultant Laboratory Director
Microbiologist
REFERENCES
1. Laboratory testing for coronavirus disease 2019 (COVID19) in suspected human cases. Interim guidance. World Health Organization.
2. Druce et al. JCM. 2011
3. N. Engl. J. Med. 2020, 382, 929–936
*DISCLAIMERS
1. This is only a professional opinion. Not for Medico legal purpose.
2. Please correlate clinically.
SPICE HEALTHCARE PRIVATE
LIMITED
Corporate Office: 320, Udyog Vihar - 4, Gurgaon, Haryana | CIN:
U33100DL2018PTC333650
Telephone No.: +91-96432-26600 | Website: [Link] | Email ID:
customercare@[Link]
------------------------- End of Report -------------------------